Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Cementless Hip Implants Are Durable for at Least Twenty Years

By HospiMedica International staff writers
Posted on 27 May 2009
A new study has found that despite the common perception that total hip replacements last only ten years, the devices are in fact extremely durable, even 20 years after surgery.

Researchers at Rush University Medical Center (Rush, Chicago, IL, USA) analyzed results for 124 hip replacements--out of 204 total hip replacements performed at Rush in the mid-1980s in a group of 184 patients ranging in age from 20 to 84 years--who were still alive 20 years or more after surgery (the findings were previously reported at 10 and 15 years). More...
The results showed that in the in the 111 patients still alive since the previous report at 15 years post-op, five metal cup implants were found to be loose, or 4% of the 124 implants. Of the original 204 hip replacements, five cases, or 2.5% of the total, had failed. Two of these five implants were revised, but three were left intact because the patients did not suffer significant symptoms. However, in nearly 20% of the patients still living 20 years post surgery, the plastic lining of the metal shell had worn enough that repeat, but less involved, surgery was required or recommended. Younger age strongly correlated with a higher risk of wear-related problems. Also, with time, the number of surgical revisions has increased due to osteolysis (bone resorption) as a result of the body's reaction to debris created by wear and corrosion of the metal implants. The study was published in the May 2009 issue of the Journal of Bone and Joint Surgery (JBJS).

"Our results confirm earlier work done at Rush and at other institutions; that cementless acetabular components work very well and that long-term biological fixation can be obtained," said lead author Craig Della Valle, M.D., an orthopedic surgeon at Rush. "With time, the number of repeat surgeries due to wear and osteolysis has increased, as have the numbers of cases of osteolysis we identified radiologically. But with the newer, more wear-resistant bearing surfaces we are now using, we believe that fewer patients today will need revision surgery for these reasons."

In this ongoing study, the researchers have been following the Harris-Galante I acetabular component, a cementless, hemispherical, porous-coated acetabular component made of unalloyed titanium with holes for screws, manufacture by Zimmer (Warsaw, IN, USA). The component design was based on research work done by Professor Jorge Galante, M.D., former chairman of orthopedics at Rush and a coauthor of this study. Earlier-generation implants, which relied on special cement to secure the device to the patient's bones, had been shown to have higher rates of failure, particularly beyond ten years.

Related Links:

Rush University Medical Center
Zimmer



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.